Which pharmaceutical company has strong research and development strength?

Kanghong Pharmaceutical:

R&D amount: 437 million.

R&D income ratio: 365,438+0.37%

R&D growth rate: 53.76% year-on-year.

Progress in research and development of core products: In biopharmaceuticals, Compaxip eye injection (trade name: rum) is undergoing international multi-center phase III clinical research. Compaxip eye injection has been approved for three indications (wet age-related macular degeneration (nAMD), visual impairment caused by diabetic macular edema (DME) and visual impairment caused by choroidal neovascularization (pmCNV) secondary to pathological myopia). Retinal vein occlusion (RVO) is currently in clinical stage III in China, and related research is proceeding as planned. In addition, KH906 eye drops used to treat trauma, chemical burns and corneal transplantation-induced neovascularization are 1 bio-innovative drugs independently developed by the company, and are currently undergoing a phase I clinical trial. 1 biological new drug KH903 with international invention patent has entered clinical phase II. There is also a new biological drug KH90 1, which is a therapeutic tumor vaccine with international patent and is also in the second phase of clinical practice. As for Chinese patent medicine, the new drug KH 1 10 (Wujiayizhi Granule) for treating Alzheimer's disease has entered clinical phase II. In terms of chemicals, the company has a number of products in the clinical research stage, and the company will plan and arrange according to its own actual situation, and gradually promote various research work.

Kelun pharmacy

R&D amount: 769 million.

R&D income ratio: 10.37%

R&D growth rate: year-on-year growth 15.48%

Progress in research and development of core products: from June 2020, 65438+1 October1to August 20, 2020, 12 was approved for marketing; Ornidazole tablets and cefradine capsules passed the consistency evaluation. Tirofiban hydrochloride sodium chloride injection, zoledronic acid injection (4mg/ 100ml), paclitaxel for injection (albumin binding type), olanzapine tablets and compound amino acid (16AA-II) glucose (48%) electrolyte injection were successively approved, which further strengthened the company's application in bacterial infections, cardiovascular and cerebrovascular diseases, tumors, mental diseases and other diseases. Dapoxetine hydrochloride is Karen's first product to enter the field of andrology. Together with the first imitation vardenafil, it will become the company's new heavy product portfolio. Tofathi tablets are important small molecule targeted drugs for the treatment of rheumatoid arthritis. Studies have shown that it has a good therapeutic effect on ulcerative colitis, active psoriasis arthritis and other related diseases. With the approval of this product, Collen officially entered the field of autoimmune diseases. Englenet tablets are the first drug approved by Collen to enter the field of diabetes. In the future, new hypoglycemic drugs under research, such as Engelnide tablets and Siglinide tablets, will form an advantageous product cluster in the field of diabetes.

From June 65438+1 October1day in 2020 to August 20, 2020, there were 16 drugs declared for production in Kelun * *, of which 9 were generic drugs (2 were declared for the first time) and 7 were conformity evaluation items. With the approval of subsequent varieties, the value of product lines such as Colleen's tumor, bacterial infection, autoimmune diseases and diabetes will be further enhanced, and it will enter the field of diagnostic imaging for the first time.

Chengdu pioneer:

R&D amount: 46.509 million yuan.

R&D income ratio: 53.59%

R&D growth rate: year-on-year growth of 25.5%

Progress in research and development of core products: the company's R&D investment is mainly used to upgrade the core technology platform, including tackling key technical problems in view of the current difficulties of DEL technology, further increasing the number of molecules, expanding molecular types and optimizing molecular properties, expanding the applicability of drug screening, and improving screening efficiency. And independent research and development of new drugs. At present, the company has about 20 research projects, most of which are in different pre-clinical stages and their development is uncertain. The projects that obtained IND include HG 146 and HG030. The phase I clinical trial of HG 146 in the treatment of multiple myeloma is under way, and the indication of HG 146 in the treatment of advanced solid tumor patients is in the pre-clinical preparation stage. On March 25th, 2020, HG030 was approved by NMPA to carry out clinical trials for advanced solid tumors with positive NTRK fusion mutation or ROS 1 fusion mutation, and preparations for clinical trials began.

Biology of zhifei

R&D investment in June-June:1.400 million yuan.

Growth rate of R&D expenditure: 37.03%

R&D revenue: 2%

Progress in research and development of core products: In the first half of 2020, the company further increased R&D investment, with the amount of R&D investment of 65,438+040,240,364.05 yuan, a year-on-year increase of 37.03%. On April 29th, 2020, the company announced that Zhifeilong Kema, a wholly-owned subsidiary, had obtained the drug registration approval of recombinant Mycobacterium tuberculosis fusion protein (EC) issued by the State Administration of Medical Supplies. On May 10, 2020, the company held a press conference on recombinant Mycobacterium tuberculosis fusion protein (EC) in Chongqing, Anhui and Beijing at the same time, which achieved a new breakthrough in the company's new drug matrix for tuberculosis. On June 23, 2020, the company disclosed the Announcement on Obtaining the Approval of novel coronavirus Vaccine Clinical Trials. The recombinant novel coronavirus vaccine (CHO cells) jointly developed by the company is currently undergoing Phase I and Phase II clinical trials.

Biology in Kang Hua:

R&D amount: 20.567 million yuan.

R&D income ratio: 4.5%

R&D growth rate: year-on-year growth of 226.39%.

Progress in research and development of core products: During the reporting period, the company paid attention to the investment in new products and technologies, including the continuous promotion of research and development of several projects based on advanced cell culture reactor technology platform, large-scale cell culture technology strength and core production technology, which kept the company's production technology in a leading position. During the reporting period, the company had eight major R&D projects, as follows:

Project name: Cultivation technology of human rabies vaccine (human diploid cells) in immobilized bioreactor